Abstract:Metallothioneins (MTs) are a group of low molecular weight (6–7KDa) proteins featured by high cysteine content which allows the proteins to bind to a diverse range of metals. MTs, of which the gene transcription can be induced by a variety of stimuli including hormones, cytokines and metal ions, have important biological functions such as storage, trafficking and homeostasis of metal ions, detoxification of heavy metals, resistance to ionizing radiation, scavenging hydroxyl radical, etc. Importantly, it has been reported that MTs play a role in oncogenesis and cancer prognosis, and are implicated in resistance of cancer cells to anticancer metallodrug cisplatin. In this work, we present a comparative study on interactions between MTs and cisplatin and ruthenium arene anticancer complexes using MALDI-TOF-MS. The results show that cisplatin coordinates to MT-I and MT-II at either pH 3.0 or 7.4, and exhibits a higher affinity to MT-II than to MT-I. The MT–Pt complexes increase significantly in content with decrease in pH values of solutions, indicative that cisplatin competes with zinc for coordination to cysteine residues on MTs and interferes with the binding of zinc to the proteins. While the ruthenium arene anticancer complexes [(η6-arene)Ru(en)Cl]PF6 (arene=benzene or biphenyl, en=ethylenediamine) hardly bind to MTs at acidic pH and coordinate to MTs at a much lower level than cisplatin at neutral pH, which may account for the less toxicity and lack of cross-resistance to cisplatin for this class of ruthenium anticancer complexes. With the MT–Pt complexes as model protein complexes, DDT, the widely used unfolding thiol-containing agent in proteomic research was shown to reduce the coordination of platinum to MTs significantly, implying that DDT used as unfolding reagent at high concentration may cause dissociation of bound metallodrug and should be applied with care.

Mass Spectrometric Studies on the Interaction of Cisplatin and Insulin

Mass Spectrometric Strategies to Improve the Identification of Pt(Ii)-Modification Sites on Peptides and Proteins

Inhibitory Effect of Cisplatin on Proteasome

Discovery Of Cisplatin Binding To Thymine And Cytosine On A Single-Stranded Oligodeoxynucleotide By High Resolution Ft-Icr Mass Spectrometry

Mass Spectrometry Evidence for Cisplatin As a Protein Cross-Linking Reagent.

Nuclear proteome analysis of cisplatin-treated HeLa cells

Systematic Identification of Proteins Binding with Cisplatin in Blood by Affinity Chromatography and a Four-Dimensional Proteomic Method.

Mass Spectrometry Assisted Assignments of Binding and Cleavage Sites of Copper(ii) and Platinum(ii) Complexes Towards Oxidized Insulin B Chain.

The Protein-Binding Behavior of Platinum Anticancer Drugs in Blood Revealed by Mass Spectrometry

Simultaneous mass spectrometry analysis of cisplatin with oligonucleotide-peptide mixtures: implications for the mechanism of action

Quantifying Intracellular Platinum Accumulation Using Inductively Coupled Mass Spectrometry

Beyond Single-Cell Analysis of Metallodrugs by ICP-MS: Targeting Cellular Substructures

Reactivity of platinum-based antitumor drugs towards a Met- and His-rich 20mer peptide corresponding to the N-terminal domain of human copper transporter 1

Proteomic Analysis of Cisplatin- and Oxaliplatin-Induced Phosphorylation in Proteins Bound to Pt-DNA Adducts.

Study on the Interactions Between Cisplatin and Cadherin by Fluorescence Spectrometry and Atomic Force Microscopy.

ICP -MS Determination of Intracellular Cisplatin in Human Lung Ladenocarcinoma Cell and Its Application of Drug -Resistance

Molecular targets of cisplatin in HeLa cells explored through competitive activity-based protein profiling strategy

A Comparative Study on Interactions of Cisplatin and Ruthenium Arene Anticancer Complexes with Metallothionein Using MALDI-TOF-MS

Sensitive Marker of the Cisplatin-DNA Interaction: X-Ray Photoelectron Spectroscopy of CL.

Pharmacokinetics of cisplatin in the absence or presence of Zengmian Yiliu granules (a traditional Chinese medicine compound) in rats determined via ICP-MS: An investigation on drug–herb interactions

ESMS and NMR investigations on the interaction of the anticancer drug cisplatin and chemopreventive agent selenomethionine †